Cosmos Health Inc. (NASDAQ: COSM) projects its new nutraceutical, Oliv18, will generate over $6 million in incremental annual U.S. revenue within the next 12 to 18 months.

The Chicago-based healthcare group expects the product to deliver approximately $4.3 million in gross profit, reflecting an anticipated gross margin of roughly 72%.

Product Details and Market Strategy

Oliv18 is a whole olive polyphenol formulation certified as USDA and EU organic. It is produced through a 100% solvent-free process and targets the cardiovascular health and antioxidant categories in the United States.

The company plans a staged rollout, beginning with direct-to-consumer e-commerce before expanding into selected retail channels. The revenue forecast incorporates internal assumptions regarding pricing, sales volumes, repeat purchase behavior, and distribution growth.

Market Context

According to Grand View Research, the U.S. cardiovascular health supplements market was estimated at $2.11 billion in 2024 and is projected to reach $3.27 billion by 2030. Precedence Research valued the U.S. antioxidants market at $1.66 billion in 2025, with projections for it to nearly double to $3.18 billion by 2035.

Greg Siokas, CEO of Cosmos Health, stated that Oliv18 extends the company's "18 Series" into established consumer wellness categories where demand is shifting toward scientifically substantiated products.

What the Numbers Show

The projected gross margin of approximately 72% indicates that the company anticipates low variable costs relative to revenue for this specific product line. This high margin profile suggests that the incremental $6 million in revenue could contribute disproportionately to operating income compared to lower-margin segments of the business, assuming fixed costs remain stable during the rollout phase.

Cosmos Health Inc. (NASDAQ: COSM) has entered an exclusive distribution agreement with Innova Healthcare to market its Sky Premium Life supplements across Saudi Arabia. The deal includes an initial purchase order of 126,000 units and grants Innova sole rights for an initial five-year period.

The agreement positions Cosmos Health to access one of the Kingdom’s largest pharmacy networks, comprising more than 250 outlets across 12 cities and villages. Innova will handle product registration, logistics, and sales through pharmacies, retail shops, and online platforms.

Deal Structure and Volume Expectations

Under the terms of the contract, Innova serves as the sole distributor for the Sky Premium Life range. The initial term is five years, with an option to renew for another five years. Innova also holds a first right of refusal to distribute new products developed or acquired by Cosmos Health during this period.

Cosmos Health expects orders to exceed 5 million units over the initial five-year term. This projection assumes current market conditions and the expansion of Innova’s retail network, which plans to grow beyond 500 pharmacies.

Market Context and Partner Profile

Saudi Arabia represents the largest healthcare market in the Gulf Cooperation Council. Grand View Research estimates the Saudi nutraceuticals market at approximately $3.26 billion in 2024, forecasting growth to $5.96 billion by 2033 at a compound annual growth rate of 6.9%.

Innova Healthcare, founded in 1994, operates under multiple banners including Innova Pharmacies and Health House. It is majority-owned by Alkhabeer Capital, which manages SAR 9.6 billion (approximately $2.5 billion) in assets. Other shareholders include Tamer Group and Cigalah Group, each holding a 12.5% stake.

Beyond its own stores, Innova Distribution supplies major retailers such as Amazon, noon, Boots, Nahdi, and Al-Dawaa. Its three Riyadh warehouses handle over 236 million units annually.

What the Numbers Show

The initial purchase order of 126,000 units represents approximately 2.5% of the total expected volume of 5 million units over the five-year term. This suggests that the majority of revenue realization from this deal is dependent on future execution and network expansion rather than immediate front-loaded sales.